These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 30287935)

  • 1. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.
    Harms PW; Harms KL; Moore PS; DeCaprio JA; Nghiem P; Wong MKK; Brownell I;
    Nat Rev Clin Oncol; 2018 Dec; 15(12):763-776. PubMed ID: 30287935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
    Barkdull S; Brownell I
    Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immune checkpoint inhibition in Merkel cell carcinoma].
    Terheyden P; Mohr A; Langan EA
    Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
    Paulson KG; Bhatia S
    J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
    Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
    Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.
    Gavvovidis I; Leisegang M; Willimsky G; Miller N; Nghiem P; Blankenstein T
    Clin Cancer Res; 2018 Aug; 24(15):3644-3655. PubMed ID: 29669806
    [No Abstract]   [Full Text] [Related]  

  • 9. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
    Vandeven N; Nghiem P
    Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
    Lahman MC; Paulson KG; Nghiem PT; Chapuis AG
    J Invest Dermatol; 2021 Aug; 141(8):1897-1905. PubMed ID: 33863500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
    Samimi M
    Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
    Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
    Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses.
    Pulliam T; Jani S; Goff PH; Bhakuni R; Tabachnick-Cherny S; Smythe K; Seaton BW; Tachiki L; Kulikauskas R; Church C; Koelle DM; Nghiem P; Bhatia S
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39401968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased H3K27me3 Expression Is Associated With Merkel Cell Polyomavirus-negative Merkel Cell Carcinoma, Especially Combined With Cutaneous Squamous Cell Carcinoma.
    Matsushita M; Iwasaki T; Wardhani LO; Kuwamoto S; Nonaka D; Nagata K; Kato M; Kitamura Y; Hayashi K
    Anticancer Res; 2019 Oct; 39(10):5573-5579. PubMed ID: 31570452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
    Marchand A; Kervarrec T; Bhatia S; Samimi M
    Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
    Walsh NM; Castonguay MC; Carter MD; Pasternak S; Ly TY; Doucette S; Hanly JG; Saggini A; Cerroni L
    Am J Dermatopathol; 2019 Nov; 41(11):819-825. PubMed ID: 31634167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
    Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
    Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts and approaches to merkel cell carcinoma.
    Babadzhanov M; Doudican N; Wilken R; Stevenson M; Pavlick A; Carucci J
    Arch Dermatol Res; 2021 Apr; 313(3):129-138. PubMed ID: 32666149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
    Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
    Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab and other recent advances in Merkel cell carcinoma.
    Bommareddy PK; Kaufman HL
    Future Oncol; 2017 Dec; 13(30):2771-2783. PubMed ID: 28976209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.